A Challenge: Controlling the Quality of Cell and Gene Therapies

Highlights of Analytical Sciences in Switzerland

Authors

  • Christoph Meyer Lonza Pharma AG, Cell and Gene Therapies, Hochbergerstrasse 60A, CH-4057 Basel
  • Alexander Sandoval Lonza Pharma AG, Cell and Gene Therapies, Hochbergerstrasse 60A, CH-4057 Basel
  • Allyson Decker Lonza Pharma AG, Cell and Gene Therapies, Hochbergerstrasse 60A, CH-4057 Basel
  • Sophia Nguyen Lonza Pharma AG, Cell and Gene Therapies, Hochbergerstrasse 60A, CH-4057 Basel
  • Susan Barr Lonza Pharma AG, Cell and Gene Therapies, Hochbergerstrasse 60A, CH-4057 Basel
  • Andreas Wirth Lonza Pharma AG, Cell and Gene Therapies, Hochbergerstrasse 60A, CH-4057 Basel

DOI:

https://doi.org/10.2533/chimia.2022.794

Keywords:

Cell and gene therapy, Good manufacturing practice, Quality control
CHIMIA Vol. 76 No. 9 (2022): Young Chemistry Professors and Ambizione Fellows

Downloads

Published

2022-09-21

Issue

Vol. 76 No. 9 (2022): Young Chemistry Professors and Ambizione Fellows in Switzerland

Section

Columns, Conference Reports

Categories

License

Copyright (c) 2022 Swiss Chemical Society

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

[1]
C. Meyer, A. Sandoval, A. Decker, S. Nguyen, S. Barr, A. Wirth, Chimia 2022, 76, 794, DOI: 10.2533/chimia.2022.794.